Paclitaxel is a mitotic inhibitor used in ovarian cancer chemotherapy. Unfortunately, due to the rapid genetic and epigenetic changes in adaptation to stress induced by anticancer drugs, cancer cells are often able to become resistant to single or multiple anticancer agents. However, it remains largely unknown how paclitaxel resistance happens. In this study, we generated a cell line of acquired resistance to paclitaxel therapy, A2780T, which is cross-resistant to other antimitotic drugs, such as PLK1 inhibitor or AURKA inhibitor. Immunoblotting revealed significant alterations in cell-cycle-related and apoptotic-related proteins involved in key signaling pathways. In particular, phosphorylation of p38, which activates H2AX, was significantly decreased in A2780T cells compared to the parental A2780 cells. Geldanamycin (GA), an inhibitor of Hsp90, sustained activation of the p38/H2AX axis, and A2780T cells were shown to be more sensitive to GA compared to A2780 cells. Furthermore, treatment of A2780 and A2780T cells with GA significantly enhanced sensitivity to paclitaxel. Meanwhile, GA cooperated with paclitaxel to suppress tumor growth in a mouse ovarian cancer xenograft model. In conclusion, GA may sensitize a subset of ovarian cancer to paclitaxel, particularly those tumors in which resistance is driven by inactivation of p38/H2AX axis.
Geldanamycin Hsp90 inhibitor Paclitaxel Ovarian cancer p38/H2AX axis
This is a preview of subscription content, log in to check access.
This work was supported by the National Natural Science Foundation of China (no. 81072135, 81372801, 81572570).
Compliance with ethical standards
All procedures performed in studies involving animals were in accordance with the ethical standards of the institution.
Ravindran J et al. Modulation of ROS/MAPK signaling pathways by okadaic acid leads to cell death via, mitochondrial mediated caspase-dependent mechanism. Apoptosis. 2011;16(2):145–61.CrossRefPubMedGoogle Scholar
Liu WH, Cheng YC, Chang LS. ROS-mediated p38alpha MAPK activation and ERK inactivation responsible for upregulation of Fas and FasL and autocrine Fas-mediated cell death in Taiwan cobra phospholipase A(2)-treated U937 cells. J Cell Physiol. 2009;219(3):642–51.CrossRefPubMedGoogle Scholar
Bu HQ et al. Induction of apoptosis by capsaicin in hepatocellular cancer cell line SMMC-7721 is mediated through ROS generation and activation of JNK and p38 MAPK pathways. Neoplasma. 2015;62(4):582–91.CrossRefPubMedGoogle Scholar
Liu H, He J, Yang J. Tumor cell p38 MAPK: a trigger of cancer bone osteolysis. Cancer Cell Microenviron. 2015;2(1):e464.PubMedGoogle Scholar
Kim HG et al. p38alpha MAPK is required for arsenic-induced cell transformation. Mol Carcinog. 2015;55(5):910–7.CrossRefPubMedGoogle Scholar
Plotnikov A et al. The MAPK cascades: signaling components, nuclear roles and mechanisms of nuclear translocation. Biochim Biophys Acta. 2011;1813(9):1619–33.CrossRefPubMedGoogle Scholar
Dong Y et al. Involvement of ROS-p38-H2AX axis in novel curcumin analogues-induced apoptosis in breast cancer cells. Mol Carcinog. 2015;55(4):323–34.CrossRefPubMedGoogle Scholar
Chiu SJ et al. Regulation of gamma-H2AX and securin contribute to apoptosis by oxaliplatin via a p38 mitogen-activated protein kinase-dependent pathway in human colorectal cancer cells. Toxicol Lett. 2008;179(2):63–70.CrossRefPubMedGoogle Scholar
Lu C et al. Serum starvation induces H2AX phosphorylation to regulate apoptosis via p38 MAPK pathway. FEBS Lett. 2008;582(18):2703–8.CrossRefPubMedGoogle Scholar
Dey A, Cederbaum AI. Geldanamycin, an inhibitor of Hsp90 increases cytochrome P450 2E1 mediated toxicity in HepG2 cells through sustained activation of the p38MAPK pathway. Arch Biochem Biophys. 2007;461(2):275–86.CrossRefPubMedPubMedCentralGoogle Scholar
Singh P et al. Inhibition of autophagy stimulate molecular iodine-induced apoptosis in hormone independent breast tumors. Biochem Biophys Res Commun. 2011;415(1):181–6.CrossRefPubMedGoogle Scholar
Cheong JH et al. Dual inhibition of tumor energy pathway by 2-deoxyglucose and metformin is effective against a broad spectrum of preclinical cancer models. Mol Cancer Ther. 2011;10(12):2350–62.CrossRefPubMedPubMedCentralGoogle Scholar
Yao F et al. An autophagy inhibitor enhances the inhibition of cell proliferation induced by a proteasome inhibitor in MCF-7 cells. Mol Med Rep. 2012;5(1):84–8.PubMedGoogle Scholar
Neckers L. Chaperoning oncogenes: Hsp90 as a target of geldanamycin. Handb Exp Pharmacol. 2006;172:259–77.CrossRefGoogle Scholar